Acadian Asset Management
ALGS icon

Acadian Asset Management’s Aligos Therapeutics ALGS Stock Holding History

Acadian Asset Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,913
Closed -$28K – 1805
2025
Q2 		$28K Buy
+3,913
New +$23.4K ﹤0.01% 1548
2024
Q4 		– Sell
-30,597
Closed -$263K – 1604
2024
Q3 		$263K Sell
30,597
-2,582
-8% -$32.1K ﹤0.01% 1276
2024
Q2 		$289K Buy
33,179
+6,859
+26% +$121K ﹤0.01% 1347
2024
Q1 		$644K Buy
26,320
+3,945
+18% +$78.5K ﹤0.01% 947
2023
Q4 		$370K Sell
22,375
-214
-0.9% -$3.68K ﹤0.01% 1099
2023
Q3 		$420K Hold
22,589
– – ﹤0.01% 1046
2023
Q2 		$547K Hold
22,589
– – ﹤0.01% 1035
2023
Q1 		$492K Buy
22,589
+9,201
+69% +$352K ﹤0.01% 1054
2022
Q4 		$318K Hold
13,388
– – ﹤0.01% 1164
2022
Q3 		$366K Buy
13,388
+815
+6% +$27.1K ﹤0.01% 1069
2022
Q2 		$380K Buy
12,573
+5,544
+79% +$188K ﹤0.01% 1051
2022
Q1 		$377K Buy
+7,029
New +$563K ﹤0.01% 1068

Other funds holding ALGS

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Acadian Asset Management's ALGS Position: Q3 2025 in Review

Acadian Asset Management sold out of Aligos Therapeutics (ALGS) in Q3 2025, closing a stake of 3,913 shares — an estimated $28K sold.

Acadian Asset Management first reported a position in ALGS in Q1 2022 and held it in 12 quarters. The position peaked at $644K in Q1 2024. 33 funds tracked by Wall St. Rank hold ALGS as of Q3 2025.

  • Acadian Asset Management reported no remaining Aligos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Acadian Asset Management sold 3,913 Aligos Therapeutics shares in Q3 2025, an estimated $28K.
  • Acadian Asset Management first reported a position in Aligos Therapeutics in Q1 2022 and held it in 12 quarters.
  • Acadian Asset Management's Aligos Therapeutics position peaked at $644K in Q1 2024.
  • 33 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2025.

Based on Acadian Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.